Rosiglitazone and imidapril alone or in combination alleviate muscle and adipose depletion in a murine cancer cachexia model

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 323-332

  Chen, Si Zeng ^a   Xiao, Jian Dong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer cachexia; Imidapril; Insulin resistance; Rosiglitazone; Treatment

Indexed keywords

ATROGIN 1; CYTOKINE; IMIDAPRIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MARKER; MUSCLE RING FINGER 1 PROTEIN; PLACEBO; ROSIGLITAZONE; UBIQUITIN PROTEIN LIGASE E3;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CACHEXIA; COLON ADENOCARCINOMA; CONTROLLED STUDY; DEPLETION; GASTROCNEMIUS MUSCLE; IN VIVO STUDY; MALE; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ADIPOSE TISSUE; ANIMALS; BIOLOGICAL MARKERS; BODY WEIGHT; CACHEXIA; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; IMIDAZOLIDINES; INFLAMMATION MEDIATORS; INSULIN; MALE; MICE; MUSCLE PROTEINS; MUSCLES; MUSCULAR ATROPHY; NEOPLASMS; ORGAN SIZE; SKP CULLIN F-BOX PROTEIN LIGASES; THIAZOLIDINEDIONES; TUMOR BURDEN; UBIQUITIN-PROTEIN LIGASES;

EID: 84893802507     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1043-1     Document Type: Article

References (57)

1. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793-9.
2. Tisdale MJ. Mechanisms of cancer cachexia. Pysiol Rev. 2009;89:381-410.
3. Palesty JA, Dudrick SJ. What we have learned about cachexia in gastrointestinal cancer. Dig Dis. 2003;21:198-213.
4. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2:862-71.
5. Khal J, Hine AV, Fearon KCH, Dejong CHC, Tisdale MJ. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol. 2005;37:2196-206.
6. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A. 2001;98:14440-5.
7. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294:1704-8.
8. Daneryd P, Hafstrom L, Svanberg E, Karlberg I. Insulin sensitivity, hormonal levels and skeletal muscle protein metabolism in tumour-bearing exercising rats. Eur J Cancer. 1995;31:97-103.
9. Sayer AA, Syddall HE, Dennison EM, Martin HJ, Phillips DI, Cooper C, et al. Grip strength and the metabolic syndrome: findings from the Hertfordshire Cohort Study. QJM. 2007;100:707-13.
10. Lee SW, Park GH, Lee SW, Song JH, Hong KC, Kim MJ. Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Nephrol Dial Transplant. 2007;22:2554-62.
11. Morley JE. Diabetes and aging: epidemiologic overview. Clin Geriatr Med. 2008;24:395-405.
12. Asp ML, Tian M, Wendel AA, Belury MA. Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int J Cancer. 2010;126:756-63.
13. Chen SZ, Qiu ZG. Combined treatment with GH, insulin, and indomethacin alleviates cancer cachexia in a mouse model. J Endocrinol. 2011;208:131-6.
14. Lundholm K, Körner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res. 2007;13:2699-706.
15. Asp ML, Tian M, Kliewer KL, Belury MA. Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia. Cancer Biol Ther. 2011;12:957-65.
16. Nam JS, Nam JY, Yoo JS, Cho M, Park JS, Ahn CW, et al. The effect of rosiglitazone on insulin sensitivity and mid-thigh low-density muscle in patients with type 2 diabetes. Diabet Med. 2010;27:30-6.
17. Sanders PM, Russell ST, Tisdale MJ. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer. 2005;93:425-34.
18. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest. 1996;97:2509-16.
19. Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GM, Clark SE, et al. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem. 2006;281:35137-46.
20. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003;361:1077-83.
21. Adigun AO, Ajayi AA. The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. Eur J Heart Fail. 2001;3:359-63.
22. Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet. 2002;359:926-30.
23. Schanze N, Springer J. Evidence for an effect of ACE inhibitors on cancer cachexia. J Cachex Sarcopenia Muscle. 2012;3:139.
24. Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol. 2007;22:577-84.
25. Mantovani G, Madeddu C. Cancer cachexia: medical management. Support Care Cancer. 2010;18:1-9.
26. Zhou W, Jiang ZW, Jiang J, Li JS. The establishment of one kind of animal model of cancer cachexia. Chin J Exp Surg. 2004;21:490-1 (in Chinese).
27. Nai YJ, Jiang ZW, Wang ZM, Li JS. Effect of nuclear factor-κB inhibitor on cancer cachexia. J Parenter Enteral Nutr. 2007;14:270-4 (in Chinese).
28. Remmele W, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract. 1993;189:862-6.
29. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000;89:2637-45.
30. MacDonald N, Easson AM, Mazurak VC, Dunn GP, Baracos VE. Understanding and managing cancer cachexia. J Am Coll Surg. 2003;197:143-61.
31. von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol. 2002;85:173-83.
32. O'Gorman P, McMillan DC, McArdle CS. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer. 2000;37:36-40.
33. MacIntosh CG, Morley JE, Wishart J, Morris H, Jansen JB, Horowitz M, et al. Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: evidence for increased CCK activity as a cause of the anorexia of aging. J Clin Endocrinol Metab. 2001;86:5830-7.
34. Steinborn W, Ander SD. Cardiac cachexia: pathophysiology and clinical implications. Basic Appl Myol. 2003;13:191-201.
35. Bosaeus I, Daneryd P, Svanberg E, Lundholm K. Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer. 2001;93:380-3.
36. Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C, et al. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer. 2010;10:363.
37. Yoshida T, Semprun-Prieto L, Sukhanov S, Delafontaine P. IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am J Physiol Heart Circ Physiol. 2010;298:H1565-70.
38. Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol. 2010;26:146-51.
39. Carson JA, Baltgalvis KA. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev. 2010;38:168-76.
40. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell. 1996;87:13-20.
41. Cai D, Frantz JD, Tawa Jr NE, Melendez PA, Oh BC, Lidov HG, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004;119:285-98.
42. Jackman RW, Kandarian SC. The molecular basis of skeletal muscle atrophy. Am J Physiol Gell Physiol. 2004;287:C834-43.
43. Coletti D, Belli L, Adamo S. Cachexia: novel perspectives for an old syndrome. Basic Appl Myol. 2006;16:131-9.
44. Remels AH, Langen RC, Gosker HR, Russell AP, Spaapen F, Voncken JW, et al. PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. Am J Physiol Endocrinol Metab. 2009;297(1):E174-83.
45. Bai YP, Liu YH, Chen J, Song T, You Y, Tang ZY, et al. Rosiglitazone attenuates NF-kappaB-dependent ICAM-1 and TNF-alpha production caused by homocysteine via inhibiting ERK1/2/p38MAPK activation. Biochem Biophys Res Commun. 2007;360:20-6.
46. Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun. 2005;336:747-53.
47. Harte A, McTernan P, Chetty R, Coppack S, Katz J, Smith S, et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation. 2005;111:1954-61.
48. Fernandes LC, Machado UF, Nogueira CR, Carpinelli AR, Curi R. Insulin secretion in Walker 256 tumor cachexia. Am J Physiol. 1990;258(6 Pt 1):E1033-6.
49. Crown AL, Cottle K, Lightman SL, Falk S, Mohamed-Ali V, Armstrong L, et al. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol (Oxf). 2002;56:723-33.
50. McCall JL, Tuckey JA, Parry BR. Serum tumor necrosis factor alpha and insulin resistance in gastrointestinal cancer. Br J Surg. 1992;79:1361-3.
51. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology. 1992;130:43-52.
52. Zander T, Kraus JA, Grommes C, Schlegel U, Feinstein D, Klockgether T, et al. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem. 2002;81:1052-60.
53. Goetze S, Bungenstock A, Czupalla C, Eilers F, Stawowy P, Kintscher U, et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR gamma-ligands. Hypertension. 2002;40:748-54.
54. Iwata M, Haruta T, Usui I, Takata Y, Takano A, Uno T, et al. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator- activated receptor -gamma. Diabetes. 2001;50:1083-92.
55. Martinez L, Berenguer M, Bruce MC, Marchand-Brustel Y, Govers R. Rosiglitazone increases cell surface GLUT4 levels in 3T3-L1 adipocytes through an enhancement of endosomal recycling. Biochem Pharmacol. 2010;79:1300-9.
56. Vijay SK, Mishra M, Kumar H, Tripathi K. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol. 2009;46:27-33.
57. Cabassi A, Tedeschi S. Zinc-α2-glycoprotein as a marker of fat catabolism in humans. Curr Opin Clin Nutr Metab Care. 2013;16:267-71.